Zhengye Biotechnology Holding (ZYBT) Common Equity (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has 3 years of Common Equity data on file, last reported at $35.2 million in Q4 2025.

• Common Equity for Q4 2025 came in at $35.2 million, down 10.89% year-over-year; the trailing twelve-month figure through Dec 2025 was $35.2 million (down 10.89% YoY), and the FY2025 annual result was $43.9 million, up 12.73% from the prior year.
• Common Equity retreated to $35.2 million in Q4 2025 per ZYBT's latest filing, from $41.7 million in the prior quarter.
• Over five years, Common Equity peaked at $47.1 million in Q4 2023 and troughed at $35.2 million in Q4 2025.
• A 3-year average of $40.9 million and a median of $40.6 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity declined 16.11% in 2024, then dropped 10.89% in 2025.
• A 3-year view of Common Equity shows it stood at $47.1 million in 2023, then slipped by 16.11% to $39.5 million in 2024, then fell by 10.89% to $35.2 million in 2025.
• Business Quant data shows ZYBT's Common Equity at $35.2 million in Q4 2025, $41.7 million in Q2 2025, and $39.5 million in Q4 2024.